Lexaria Bioscience Corp. (LEXX) shareholders
Close on Nov 17, 2026Market cap $103.61MP/E –Yield –
Ownership
Who owns Lexaria Bioscience's shares
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard Christopher | Chief Executive Officer, Director | 65,000 | 0.26% | Jul 30, 2025 |
| John Martin Docherty | President & CSO, Director | 59,451 | 0.24% | Jul 30, 2025 |
| Vanessa Carle | Secretary | 750 | 0.00% | Jul 30, 2025 |
| Michael Elliot Shankman | Chief Financial Officer | – | – | May 16, 2025 |
| Christopher Bunka | Director | 555,455 | 2.24% | Mar 18, 2026 |
| William Edward McKechnie | Director | 18,191 | 0.07% | Jul 30, 2025 |
| Albert L. Reese Jr | Director | 10,917 | 0.04% | May 16, 2025 |
| Nicholas W. Baxter | Director | 11,000 | 0.04% | May 16, 2025 |
| Baljinder Bhullar | Director | 13,000 | 0.05% | May 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christopher Bunka Director | Mar 17, 2026 | Gift | −100,000 | – | – | 273,543 |
| Christopher Bunka Director | Jul 30, 2025 | Buy | +11,900 | $0.91 | $10.83K | 281,912 |
| Vanessa Carle Secretary | Jul 29, 2025 | Buy | +750 | $0.91 | $683 | 750 |
| Richard Christopher Chief Executive Officer, Director | Jul 29, 2025 | Buy | +15,000 | $0.91 | $13.65K | 65,000 |
| William Edward McKechnie Director | Jul 29, 2025 | Buy | +5,000 | $0.91 | $4.55K | 18,191 |
| John Martin Docherty President & CSO, Director | Jul 29, 2025 | Buy | +5,376 | $0.93 | $5.00K | 5,376 |
| Christopher Bunka Director | Jul 29, 2025 | Buy | +15,600 | $0.92 | $14.35K | 270,012 |
| Christopher Bunka Director | Jan 7, 2025 | Award | +100,000 | – | – | 373,543 |
| Richard Christopher Chief Executive Officer | Dec 3, 2024 | Buy | +27,172 | $2.47 | $67.11K | 50,000 |
| Richard Christopher Chief Executive Officer | Dec 2, 2024 | Buy | +22,828 | $2.24 | $51.13K | 22,828 |
| Catherine C. Turkel Director | Aug 12, 2024 | Buy | +1,600 | $3.13 | $5.01K | 3,100 |
| Vanessa Carle Secretary | Jul 31, 2024 | Sale | −2,567 | $4.00 | $10.27K | 0 |
| Vanessa Carle Secretary | May 14, 2024 | Option exercise | +2,500 | $1.15 | $2.88K | 2,567 |
| Catherine C. Turkel Director | Feb 9, 2023 | Buy | +1,500 | $2.84 | $4.26K | 1,500 |
| Gregory Downey Chief Financial Officer | Oct 14, 2022 | Buy | +121 | $2.09 | $253 | 1,954 |
| Gregory Downey Chief Financial Officer | Oct 14, 2022 | Award | +121 | $2.09 | $253 | 1,954 |
| Christopher Bunka Chief Executive Officer, Director | Oct 13, 2022 | Buy | +16,600 | $2.10 | $34.86K | 254,412 |
| Christopher Bunka CEO, Director | Oct 13, 2022 | Award | +16,600 | $2.10 | $34.86K | 254,412 |
| Christopher Bunka Chief Executive Officer, Director | Oct 12, 2022 | Buy | +21,900 | $1.99 | $43.58K | 237,812 |
| Christopher Bunka CEO, Director | Oct 12, 2022 | Award | +21,900 | $1.99 | $43.58K | 237,812 |
| Albert L. Reese Jr Director | May 24, 2022 | Award | +5,000 | $1.96 | $9.80K | 10,917 |
| Albert L. Reese Jr Director | May 20, 2022 | Award | +1,799 | $2.01 | $3.62K | 5,917 |
| Albert L. Reese Jr Director | May 19, 2022 | Award | +1,501 | $2.01 | $3.02K | 4,118 |
| Albert L. Reese Jr Director | May 18, 2022 | Award | +1,700 | $2.01 | $3.42K | 2,617 |
| Christopher Bunka CEO, Director, 10% owner | Nov 10, 2020 | Buy | +10,000 | $0.20 | $2.00K | 6,445,844 |
| Christopher Bunka CEO, Director, 10% owner | Nov 10, 2020 | Buy | +25,500 | $0.19 | $4.85K | 6,477,344 |
| Christopher Bunka CEO, Director, 10% owner | Nov 10, 2020 | Buy | +6,000 | $0.20 | $1.20K | 6,451,844 |
| Christopher Bunka CEO, Director, 10% owner | Nov 9, 2020 | Buy | +6,500 | $0.20 | $1.30K | 6,413,844 |
| Christopher Bunka CEO, Director, 10% owner | Nov 9, 2020 | Buy | +22,000 | $0.20 | $4.40K | 6,435,844 |
| Christopher Bunka CEO, Director, 10% owner | Nov 9, 2020 | Buy | +37,500 | $0.22 | $8.25K | 6,379,344 |
| Christopher Bunka CEO, Director, 10% owner | Nov 9, 2020 | Buy | +10,000 | $0.20 | $2.00K | 6,389,344 |
| Christopher Bunka CEO, Director, 10% owner | Nov 9, 2020 | Buy | +10,000 | $0.21 | $2.10K | 6,399,344 |
| Christopher Bunka CEO, Director, 10% owner | Nov 9, 2020 | Buy | +8,000 | $0.20 | $1.60K | 6,407,344 |
| Christopher Bunka CEO, Director, 10% owner | Nov 6, 2020 | Buy | +60,000 | $0.21 | $12.60K | 6,341,844 |
| William Edward McKechnie Director | Jul 23, 2020 | Option exercise | +110,000 | $0.17 | $18.70K | 395,738 |
| Christopher Bunka CEO, Director, 10% owner | May 6, 2020 | Award | +200,000 | $0.23 | $46.00K | 6,281,844 |
| Nicholas W. Baxter Director | Dec 20, 2019 | Option exercise | +110,000 | $0.10 | $11.00K | 330,000 |
| Allan Horst Spissinger Chief Financial Officer | Feb 15, 2019 | Option exercise | +50,000 | $0.37 | $18.50K | 119,116 |
| John Martin Docherty President, Director | Aug 31, 2018 | Award | +36,500 | $2.07 | $75.56K | 1,622,250 |
| Christopher Bunka CEO, Director, 10% owner | Aug 31, 2018 | Award | +32,500 | $2.07 | $67.28K | 7,126,304 |
| Christopher Bunka CEO, Director, 10% owner | Aug 14, 2018 | Gift | −500,000 | – | – | 7,093,804 |
| Christopher Bunka CEO, Director, 10% owner | Aug 3, 2018 | Award | +81,250 | $1.24 | $100.75K | 7,593,804 |
| John Martin Docherty Director, 10% owner | Aug 3, 2018 | Award | +182,500 | $1.32 | $240.90K | 1,494,500 |
| John Martin Docherty Director, 10% owner | Aug 3, 2018 | Award | +91,250 | $1.24 | $113.15K | 1,585,750 |
| Christopher Bunka CEO, Director, 10% owner | Jun 18, 2018 | Option exercise | +247,500 | $0.09 | $22.28K | 7,512,554 |
| Christopher Bunka CEO, Director, 10% owner | Jun 18, 2018 | Option exercise | +450,000 | $0.14 | $63.00K | 6,081,844 |
| William Edward McKechnie Director | May 31, 2018 | Sale | −2,100 | $1.90 | $3.99K | 285,738 |
| William Edward McKechnie Director | May 30, 2018 | Sale | −47,800 | $1.90 | $90.82K | 287,938 |
| William Edward McKechnie Director | May 30, 2018 | Sale | −100 | $1.91 | $191 | 287,838 |
| Christopher Bunka CEO, Director, 10% owner | Dec 1, 2017 | Award | +29,475 | $0.82 | $24.17K | 7,265,054 |
| Allan Horst Spissinger CFO | Dec 1, 2017 | Award | +41,666 | $0.82 | $34.17K | 69,166 |
| William Edward McKechnie Director | Dec 1, 2017 | Award | +14,634 | $0.82 | $12.00K | 335,738 |
| John Martin Docherty Director, 10% owner | Dec 1, 2017 | Award | +35,000 | $0.82 | $28.70K | 1,312,000 |
| William Edward McKechnie Director | Aug 28, 2017 | Award | +32,433 | $0.37 | $12.00K | 321,104 |
| John Martin Docherty President, Director | Jun 22, 2017 | Award | +210,000 | $0.30 | $63.00K | 1,277,000 |
| Christopher Bunka CEO, Director, 10% owner | Jun 21, 2017 | Award | +210,000 | $0.30 | $63.00K | 5,631,844 |
| William Edward McKechnie Director | May 31, 2017 | Award | +35,294 | $0.34 | $12.00K | 288,671 |
| William Edward McKechnie Director | May 31, 2017 | Award | +35,249 | $0.34 | $11.98K | 288,626 |
| William Edward McKechnie Director | Feb 22, 2017 | Award | +29,091 | $0.55 | $16.00K | 253,377 |
| William Edward McKechnie Director | Oct 11, 2016 | Award | +114,286 | $0.14 | $16.00K | 224,286 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lexaria Bioscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,550 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?